Retrospective evaluation of epithelial-on corneal collagen cross-linking (CXL) in older patients

Poster Details

First Author: R.Rubinfeld USA

Co Author(s):    S. Feldman   K. Hatch   R. Malahotra   D. Wallace   J. Davidorf   T. McCall

Abstract Details

Purpose:

To evaluate the safety, efficacy, and outcomes of epithelial-on CXL in patients age 35 and over diagnosed with pre-Op ectatic corneal disease.

Setting:

Center for Excellence in Eye Care, Miami, Fl

Methods:

Eyes of patients aged 35 or older with a pre-Op diagnosis of keratoconus, pellucid marginal degeneration (PMD), post-LASIK ectasia, or post-PRK ectasia that were treated with Epi-on CXL unilaterally or bilaterally were evaluated A minimum of 2 months follow-up was required and patients with corneal opacities and/or complications were excluded from this analysis. Outcome measures included UCVA, BSCVA, astigmatism measures, pentacam data, and topography data.

Results:

88 eyes met inclusion criteria, 73% were male. The average age of patients was 47. Patients had an average follow-up of 7 months (minimum of 2 months, maximum of 20 months). 73% of eyes had a pre-Op diagnosis of keratoconus, 4.6% of eyes had a pre-Op diagnosis of PMD, and 22.73% had a pre-Op diagnosis of post-LASIK ectasia. The percent of patients with a UCVA of 20/50 or better and 20/40 or better increased from 9% to 19% and 8% to 14%, respectively, at the latest post-Op visit. The percent of patients with a BSCVA of 20/40 or better and 20/30 or better increased from 52% to 59% and 31% to 36%, respectively, at the latest post-Op visit. 69%, 65%, and 61% of eyes had a reduction of 0.5D or more in astigmatism, spherical equivalent, and 2mm astigmatism, respectively. 40% and 51% of eyes experienced reduction in Holladay mean K and Magellan mean K, respectively. 59% of eyes experienced improvement in topography I_S ratio of 0.1 or more. 36% of eyes had a reduction in Pachymetry apex of 5 microns or more on pentacam

Conclusions:

Epithelial-On CXL is proven safe and effective for patients that are age 35 and older diagnosed with pre-Op corneal ectatic disease. FINANCIAL DISCLOSURE?: ... has significant investment interest in a company producing, developing or supplying product or procedure presented